联系客服

000766 深市 通化金马


首页 公告 通化金马:关于2019年年度报告及相关文件的补充更正公告

通化金马:关于2019年年度报告及相关文件的补充更正公告

公告日期:2020-07-20

通化金马:关于2019年年度报告及相关文件的补充更正公告 PDF查看PDF原文

    证券代码:000766            证券简称:通化金马              公告编号:2020-47

            通化金马药业集团股份有限公司关于

          2019年年度报告及相关文件的补充更正公告

        本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚假

    记载、误导性陈述或重大遗漏。

        通化金马药业集团股份有限公司(以下简称“公司”)于 2020 年 5 月 26 日

    收到深圳证券交易所《关于对通化金马药业集团股份有限公司的年报问询函》(公

    司部年报问询函〔2020〕第 111 号)(以下简称“问询函”),根据问询函的有关

    要求,经公司认真核实,公司 2019 年年度报告、2019 年度审计报告及相关商

    誉减值测试评估报告中部分内容存在填报错误,现进行补充更正,具体情况如下:

        一、更正事项

        1、《2019 年年度报告全文》“第十二节 财务报告\七、合并财务报表项目注

    释\71、信用减值损失”

        更正前:

                                                                          单位: 元

            项目                      本期发生额                    上期发生额

其他应收款坏账损失                            -6,544,330.76                -4,791,475.48

应收账款坏账损失                              -40,826,602.91                -17,913,133.70

合计                                        -47,370,933.67                -22,704,609.18

        更正后:

                                                                          单位: 元

            项目                      本期发生额                    上期发生额

其他应收款坏账损失                            -4,057,330.76                -4,791,475.48

应收账款坏账损失                              -43,313,602.91                -17,913,133.70

合计                                        -47,370,933.67                -22,704,609.18

        2、《2019 年审计报告》“财务报表附注\五、合并财务报表主要项目注释\45、

    信用减值损失”

        更正前:


                                                                          单位:元

              项目                          本期发生额                        上期发生额

应收账款坏账损失                                    40,826,602.91                    17,913,133.70

其他应收款坏账损失                                    6,544,330.76                      4,791,475.48

              合计                                  47,370,933.67                    22,704,609.18

      更正后:

                                                                          单位:元

              项目                          本期发生额                        上期发生额

应收账款坏账损失                                    43,313,602.91                    17,913,133.70

其他应收款坏账损失                                    4,057,330.76                      4,791,475.48

              合计                                  47,370,933.67                    22,704,609.18

      3、《通化金马药业集团股份有限公司以财务报告为目的拟进行商誉减值测

  试涉及的哈尔滨圣泰生物制药有限公司含商誉资产组可收回金额项目资产评估

  报告》“一、委托人、被评估单位及其他评估报告使用人概况\(二)被评估单

  位概况\9、圣泰生物制药近年的财务状况及经营状况\2016-2019 年经营状况表

  (母公司报表口径)”

      更正前:

                                                  金额单位:人民币万元

                项目              2016 年度      2017 年度      2018 年度      2019 年度

    一、营业收入                      49,756.77      89,791.32      111,768.62      87,143.08

            减:营业成本              11,705.22      13,447.84      13,403.74      12,985.67

          营业税金及附加              1,065.04      1,832.14          816.01        862.97

              销售费用                  9,803.13      41,900.56      61,705.15      51,652.13

              管理费用                  4,948.59      5,915.22        3,574.34      3,115.99

              研发费用                                                  4,178.16      4,316.79

              财务费用                    324.00        690.67          954.46        108.36

          其中:利息费用                                              1,366.36      2,109.11

              利息收入                                                    -81.36        855.90

            资产减值损失                  174.13        798.81          938.55        -393.95

            信用减值损失                                                              -7,583.52


        加:投资收益(损失          290.24        689.34          965.40          78.97
以“—”填列)

      资产处置收益                  -77.22                          -1.41

        其他收益                                  493.03        2,048.30        990.60

二、营业利润(亏损以“—”填      22,375.15      27,986.06      31,089.01      7,193.27
列)

      加:营业外收入                461.61          35.34          31.97          17.05

 其中:非流动资产处置利得

      减:营业外支出                                            66.26                32.00

 其中:非流动资产处置损失

三、利润总额(亏损总额以“—”      22,836.76      28,021.40      31,054.72      7,178.32
填列)

      减:所得税费用              1,154.31      1,154.31        1,154.31      1,154.31

四、净利润(净亏损以“—”号      21,682.45      26,867.09      29,900.41      6,024.01
填列)

  更正后:

                                              金额单位:人民币万元

          项目              2016 年度      2017 年度      2018 年度      2019 年度

一、营业收入                      49,756.77      89,791.32      111,768.62      87,143.08

      减:营业成本              11,705.22      13,447.84      13,403.74      12,985.67

      营业税金及附加              1,065.04      1,832.14          816.01        862.97

        销售费用                  9,803.13      41,900.56      61,705.15      51,652.13

        管理费用                  4,948.59      5,915.22        3,574.34      3,115.99

        研发费用                                                  4,17
[点击查看PDF原文]